Mouse Genome Informatics
hm
    Cd36tm1Mfe/Cd36tm1Mfe
involves: 129S1/Sv * C57BL/6
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
homeostasis/metabolism
N
• glycogen synthesis is normal (J:123605)
• exhibit a significant reduction in tolerance to ischemia; cardiac output is significantly lower and end-diastolic pressure is significantly higher after ischemia, regardless of whether the perfusate is with or without fatty acids, compared to controls (J:83611)
• survival of hearts is lower (53%) than that of wild-type (80%) after a 6-min ischemic insult (J:83611)
• recovery after ischemia is similar to controls in another study which also saw no adverse effect on survival (J:112746)
• lower fasting glucose levels
• decrease in glycogen levels in the heart
• plasma levels are 2 fold higher than for controls, even when fasted
• increased leptin mRNA in adipocytes
• leptin response to intragastric glucose administration is strongly enhanced and persists at least 4 hours
• blood levels are decreased
• the uptake of oleate, a long chain fatty acid, by adipoctyes is reduced at low fatty acid:BSA ratios, indicating the absence of high affinity uptake in these cells
• adipocytes exhibit an increased incorporation of palmitate into diacylglycerol
• elicited peritoneal macrophages exhibit a 40-47% decrease in binding of oxidized LDL at saturation and a 63% decrease in cell association
• 50% reduction in oleic acid uptake in the first third of the small intestine
• also reduced uptake in the middle third but not in the distal third
• reduced incorporation of fatty acids into triglycerides in the first third of the small intestine
• decreased secretion of newly synthesized triglycerides in the first third but not the remainder of the small intestine
• more cholesterol retained in the intestinal lumen
• 50% reduction in cholesterol output to lymph
• cholesterol uptake in the first third of the small intestine is reduced more than 60%
• no defect in cholesterol uptake in the distal two-thirds of the small intestine
• plasma beta hydroxybutyrate levels are increased
• high density lipoprotein (HDL) particles are larger and contain increased phospholipid
• higher fasting and nonfasting levels of cholesterol
• increase in cholesterol level is mainly due to an increase in the HDL fraction
• higher fasting levels of nonesterified free fatty acids
• reduced incorporation of glucose into triglycerides
• higher fasting levels of triacylglycerol, mainly within the very low density lipoprotein fraction
• decrease in triglyceride levels in the heart
• unadjusted metabolic rate is reduced by 15%
• rate adjusted to body weight is normal

cardiovascular system
• increase in the heart/body weight ratio, although exhibit no significant differences in body and heart weights
• heart exhibits a significant decrease in palmitate oxidation and ATP levels, however cardiac output and end-diastolic pressure is normal under nonischemic conditions (J:83611)
• lower palmitate oxidation rates relative to controls offset by increased glucose oxidation levels with normal ATP production in another study (J:112746)
• cardiac work in non-ischemic hearts elevated relative to controls in another study (J:112746)
• increase in glucose uptake in the heart
• exhibit a significant reduction in tolerance to ischemia; cardiac output is significantly lower and end-diastolic pressure is significantly higher after ischemia, regardless of whether the perfusate is with or without fatty acids, compared to controls (J:83611)
• survival of hearts is lower (53%) than that of wild-type (80%) after a 6-min ischemic insult (J:83611)
• recovery after ischemia is similar to controls in another study which also saw no adverse effect on survival (J:112746)

muscle
• increase in glucose uptake in the heart

growth/size
• total body fat about 38% lower than in controls
• lean mass normal
• body size smaller than in controls (J:123605)
• weight difference from controls significant after 12 weeks of age (J:126461)
• gain less weight than controls
• weight difference from controls significant after 12 weeks of age

digestive/alimentary system
• small intestine is longer than in controls
• increased glucose uptake rate in the first third of the small intestine
• 50% reduction in oleic acid uptake in the first third of the small intestine
• also reduced uptake in the middle third but not in the distal third
• reduced incorporation of fatty acids into triglycerides in the first third of the small intestine
• decreased secretion of newly synthesized triglycerides in the first third but not the remainder of the small intestine
• more cholesterol retained in the intestinal lumen
• 50% reduction in cholesterol output to lymph
• cholesterol uptake in the first third of the small intestine is reduced more than 60%
• no defect in cholesterol uptake in the distal two-thirds of the small intestine

adipose tissue
• total body fat about 38% lower than in controls
• lean mass normal
• epididymal fat pads weigh less than in controls

skeleton
• significantly reduced bone mass

behavior/neurological
• food intake reduced 20%

cellular
• increase in glucose uptake in the heart

Mouse Models of Human Disease
OMIM IDRef(s)
Platelet Glycoprotein IV Deficiency 608404 J:56081